TICKERNERD
Menu
PLSEPLSEHealthcare · Medical Instruments & Supplies

PLSE Stock Forecast: Pulse Biosciences, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$50
+5.43% on the day

The 4 Wall Street analysts covering Pulse Biosciences, Inc. hold a median 12-month price target of $44 — -12.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$3.6B
Ticker Nerd rank
42 / 100
Median analyst target
$44
Analysts covering
4
Total return, dividends reinvested
1W
+13.3%
1M
+66.7%
YTD
+267.4%
1Y
+215.3%
From 52W high
0.0%
From 52W low
+298.5%
$13
$50
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PLSE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Pulse Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
42 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
98
Accruals
80
Issuance
58
Revisions
53
Growth
36
Value
31
Volatility
30
Size
29
Quality
12

Momentum (98): The shares have been drifting up relative to others.

Quality (12): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PLSE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PLSE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26PLSEHigh $58Median $44Low $35

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $35Median $44High $58

The green dot is the last close — the median target sits −12.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Aug 2026NeedhamInitiatesBuy$58
10 Aug 2026Canaccord GenuityMaintainsBuy$32 → $43
4 June 2026Canaccord GenuityInitiatesBuy$32
4 June 2026Canaccord GenuityInitiatesBuy—
7 July 2025OppenheimerInitiatesOutperform—
21 Sept 2022Maxim GroupDowngradeHold—
13 May 2022HC Wainwright & Co.DowngradeNeutral—
1 Apr 2022HC Wainwright & Co.MaintainsBuy—
1 Apr 2022Stephens & Co.MaintainsOverweight—
10 Feb 2022HC Wainwright & Co.MaintainsBuy—
16 Nov 2021HC Wainwright & Co.MaintainsBuy—
27 July 2021Stephens & Co.InitiatesOverweight—
11 Mar 2021Maxim GroupInitiatesBuy—
26 Jan 2021HC Wainwright & Co.MaintainsBuy—
12 May 2020H.C. WainwrightUpgradeBuy—
12 May 2020HC Wainwright & Co.UpgradeBuy—
14 Feb 2020H.C. WainwrightDowngradeNeutral—
14 Feb 2020HC Wainwright & Co.DowngradeNeutral—
25 Feb 2019H.C. WainwrightInitiatesBuy—
25 Feb 2019HC Wainwright & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PLSE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

PLSE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Pulse Biosciences, Inc. (PLSE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−46.7×

Cheaper than 98% of US stocks

Price / sales
3034.7×

Cheaper than 1% of US stocks

Price / book
35.9×

Cheaper than 3% of US stocks

EV / EBITDA
−42.4×

Cheaper than 93% of US stocks

Growth & margins
Revenue growth (YoY)
8.2%

Higher than 48% of US stocks

Earnings growth (YoY)
—
Gross margin
37.1%

Higher than 46% of US stocks

Operating margin
−5823.0%

Higher than 3% of US stocks

Net margin
−54.0%

Higher than 10% of US stocks

Returns & dividend
Return on equity
−78.5%

Higher than 16% of US stocks

Return on assets
−44.3%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PLSE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
PLSEPulse Biosciences, Inc.$3.6B
42
WRBYWarby Parker, Inc.$3.3B
30
ICUIICU Medical, Inc.$4.5B
97
NVSTEnvista Holdings Corp.$4.5B
98
ATRCAtriCure, Inc.$2.5B
94
XRAYDentsply Sirona, Inc.$2.2B
91
MMSIMerit Medical Systems, Inc.$5.4B
92

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Pulse Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PLSE news & analysis

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire · 18 Aug 2026neutral

Pulse Biosciences announced that its Compensation Committee granted equity inducement awards to five new employees under the company's 2017 Inducement Equity Incentive Plan, outside its standard 2017 Equity Incentive Plan. The awards were approved and issued.

Why it matters — The grants signal continued hiring as Pulse Biosciences builds out its team around its proprietary Nanosecond Pulsed Field Ablation technology, keeping equity compensation in line with Nasdaq listing rules.

Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform

MarketBeat · 16 Aug 2026positive

Pulse Biosciences CEO and Co-Chairman Paul LaViolette presented at the Canaccord Genuity 46th Annual Global Growth Conference, positioning the company's nanosecond pulsed field ablation technology as a potential next-generation treatment platform for atrial fibrillation and other conditions.

Why it matters — A PLSE watcher would care because the CEO's framing of the nanosecond PFA platform highlights its potential as a next-generation treatment for AFib, a key part of the company's growth strategy.

Pulse Biosciences, Inc. (PLSE) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Seeking Alpha published the Q2 2026 earnings call transcript for Pulse Biosciences, Inc. (PLSE), covering the company's quarterly earnings discussion for the period. The item consists solely of the transcript's release and provides no additional details about its content.

Why it matters — A PLSE watcher can use the earnings call transcript to review management's own commentary on the company's quarterly results and outlook.

Pulse Biosciences Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026neutral

Pulse Biosciences reported second-quarter revenue of $434,000 and highlighted the accelerated clinical development of its nanosecond pulsed field ablation (nsPFA) technology for treating atrial fibrillation.

Why it matters — A PLSE watcher would care because the company's progress in advancing nsPFA technology into atrial fibrillation treatment signals a key step in its clinical and product development pipeline.

Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research · 7 Aug 2026negative

Pulse Biosciences reported a second-quarter loss of $0.36 per share, wider than the Zacks Consensus Estimate of a $0.31 loss and compared with a $0.28 per-share loss a year earlier. The results also missed revenue estimates.

Why it matters — For PLSE watchers, the Q2 loss came in worse than both analyst expectations and the prior-year figure, indicating weaker-than-expected financial performance for the quarter.

FAQ

Frequently asked questions about PLSE stock

What is the PLSE stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Pulse Biosciences, Inc. have a median 12-month price target of $44, with estimates ranging from $35 to $58. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PLSE stock a buy right now?

Of the 4 analysts covering Pulse Biosciences, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pulse Biosciences, Inc. 42 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PLSE?

As at 22 Aug 2026, Pulse Biosciences, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).

Will PLSE stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies -12.8% from the last close, and Ticker Nerd's factor model ranks Pulse Biosciences, Inc. 42 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PLSE stock forecast for 2030?

No analyst covering Pulse Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PLSE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $35 to $58 over the next 12 months.

How has PLSE stock performed over the past year?

Pulse Biosciences, Inc. returned +215.3% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pulse Biosciences, Inc. do?

Pulse Biosciences, Inc. is a bioelectric medicine company specializing in the development of novel Nanosecond Pulsed Field Ablation (nsPFA) platforms.

What is the latest news on PLSE?

The most recent item we track (Business Wire, 18 Aug 2026): "Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". Pulse Biosciences announced that its Compensation Committee granted equity inducement awards to five new employees under the company's 2017 Inducement Equity Incentive Plan, outside its standard 2017 Equity Incentive Plan. The awards were approved and issued.

Company

About Pulse Biosciences, Inc.

Pulse Biosciences, Inc. is a bioelectric medicine company specializing in the development of novel Nanosecond Pulsed Field Ablation (nsPFA) platforms. Its primary focus centers on the patented nPulse technology, which enables precise, non-thermal ablation of soft tissues for applications in dermatology, cardiology, and surgical procedures. Key products include the CellFX System for treating benign skin lesions, the CellFX nsPFA Percutaneous Electrode for soft tissue ablation, the CellFX nsPFA Cardiac Clamp for surgical atrial fibrillation treatment, and the CellFX nsPFA 360° Cardiac Catheter for circumferential cardiac ablation. The company also offers the CellFX Console, a tunable, software-enabled platform supporting physician workflows. Pulse Biosciences, Inc. targets high-impact healthcare areas such as restoring normal cardiac rhythm in atrial fibrillation patients and ablating benign thyroid nodules and tumors. Founded in 2014 and headquartered in Miami, Florida, it plays a pivotal role in advancing minimally invasive, bioelectric therapies within the medical instruments and supplies sector.

CEO Mr. Paul Arthur LaViolette M.B.A. · 116 employees · United States · https://www.pulsebiosciences.com